Brain Tumor
Awareness Month
Learn how you can support the brain cancer community throughout the month of May and beyond.
Learn More
the science
of research
Our Director of Science, Ze’ev Bomzon, discusses his research on Tumor Treating Fields and the importance of effectively explaining the technology.
Learn More
2016 Novocure
annual report
View our 2016 Annual Report to learn where we've been and where we are headed in 2017 and beyond.
Learn More
innovation
at work
Our second generation Optune System is smaller and less than half the weight of our first generation Optune System. See more on the innovation behind our redesigned Tumor Treating Fields delivery system.
Learn More
patientforward
Martin Romero Sanchez, a glioblastoma patient, and his wife, Karma Punwasi, have found support by connecting with other brain cancer survivors and caregivers, along with young adults affected by cancer.
Learn More
working one-on-one with our patients
Our Device Support Specialists (DSSs) embody our patient-forward mission and set our business apart from other companies that market cancer therapies.
Learn Moretreating cancer with electric fields
treating cancer with electric fields
Surgery, chemotherapy and radiation are the best-known methods for treating cancer. At TEDMED in 2011, our Executive Chairman Bill Doyle presents our therapy, Tumor Treating Fields, as a potential fourth modality in cancer care.
the story
of Novocure
In 2000, our founder Professor Yoram Palti sought to leverage his expertise in biophysics to develop a new way to treat cancer that would destroy tumor cells while sparing healthy tissue and avoiding many of the life-altering side effects of existing cancer therapies. Novocure has grown into an international oncology company with more than 450 employees and operations in the U.S., Europe and Asia.
Learn More
Tumor Treating Fields, or TTFields, are low intensity, alternating electric fields.
TTFields disrupt cancer cell division through physical interactions with key molecules during mitosis. Our non-invasive treatment targets solid tumors.
OUR THERAPY
explore our clinical pipeline.
Our research shows that TTFields have an antimitotic effect in more than 15 solid tumor types in culture and in eight in vivo tumor models.
OUR PIPELINE
we are dedicated to improving the lives of cancer patients.
Patients remain at the heart of the work we do every day. Learn more about our patients, their families and the people working to deliver patient-forward therapies to treat cancer.
PATIENT-FORWARD